- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01490762
Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler
A Phase 1, Open-label, Randomized, Crossover Design Clinical Trial in Healthy Normal Volunteers to Evaluate Insulin Exposure and Effect Following Inhalation of Technosphere® Insulin Inhalation Powder at Multiple Doses Using the Gen2C Inhaler
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Healthy Normal Volunteers will be randomized to a sequence of 4 different doses of Technosphere® Insulin (TI), inhaled using the Gen2C device, and one dose of subcutaneously injected Regular Human Insulin. A euglycemic clamp procedure will be performed at each dosing visit. The purpose of this study is to determine the insulin dose proportionality/linearity of Technosphere® Insulin (TI) Inhalation Powder based on the AUCo-180 after administration of the following doses using the Gen2C inhaler:
- 10 U (one 10 U cartridge)
- 30 U (one 10 U and one 20 U cartridge)
- 60 U (three 20 U cartridges)
- 80 U (four 20 U cartridges)
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Chula Vista, California, United States, 91911
- Profil Institute for Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women aged 18 to 55 years who are considered healthy based on screening physical examination, medical history, clinical chemistry, and urinalysis
- Good venous access for blood draws
- No smoking in the previous 6 months (including cigarettes, cigars, pipes) and negative urine cotinine testing (< 100 ng/mL)
- Body mass index (BMI) < 32 kg/m2
- FEV1 = 80% of the Third National Health and Nutrition Examination Survey (NHANES III) predicted
- FVC = 80% of the Third National Health and Nutrition Examination Survey (NHANES III) predicted
- Written informed consent provided
Exclusion Criteria:
- Blood donation of 500 mL within the previous 56 days
- Fasting blood sugar >130 mg/dL
- History of coronary artery disease, peripheral vascular disease, or congestive heart failure
- Allergy to study drug, food, or other study material (eg, peanuts, soy products)
- Clinically significant active or chronic illness
- History of asthma, COPD, or any other clinically relevant chronic lung disease
- Respiratory tract infection within 4 weeks before screening
- Donation of blood within 3 months before screening
- History of drug or alcohol abuse
- Positive urine drug screen
- Clinically significant screening ECG, physical examination, laboratory test, or vital sign abnormality
- Any subject who, in the opinion of the PI or a designee, appears to not be qualified for this study
- Exposure to any other investigational drug or device within 30 days before treatment or within 90 days before treatment for drugs known to modify glucose metabolism (except metformin
- History of malignancy within the 5 years before screening (other than basal cell carcinoma)
- History of human immunodeficiency virus (HIV) infection or hepatitis B or C
- Women who are pregnant, lactating, or planning to become pregnant during the clinical study period
- Any subject who at Visit 2 has a blood glucose value = 150 mg/dL 2 hours after the meal, should be discussed with the MKC medical monitor and may be removed as potentially having impaired glucose tolerance
- Inability, in the opinion of the PI or a designee, to adequately inhale TI Inhalation Powder
- Women of childbearing potential (defined as premenopausal and not surgically sterilized or postmenopausal for fewer than 2 years) not practicing adequate birth control. Adequate birth control is defined as using oral, percutaneous, or transdermal contraceptives; condoms and diaphragms (double barrier) with a spermicide; or intrauterine devices. Postmenopausal for the purposes of this clinical study includes experiencing amenorrhea for 2 or more years or being surgically sterile
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Regular Human Insulin
Subcutaneous injection
|
Subcutaneous injection
|
Experimental: TI and Regular Human Insulin
All subjects have 4 clamp procedures with 10, 30, 60,80 units of TI and 1 clamp with 15 IU Regular Human Insulin
|
Inhalation Powder
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
area-under-the-serum insulin concentration versus time curve (AUC0-240min) for inhaled Technosphere Insulin (TI) post-dosing of a TI dose (10 U, 30 U, 60 U or 80U). Time points: 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180 and 240 minutes post-TI dosing
Time Frame: crossover 4 times over the course of up to 5 weeks
|
crossover 4 times over the course of up to 5 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area-under-the-serum insulin concentration versus time curve (AUC0-240min) for inhaled Technosphere Insulin (TI) compared to that of subcutaneous regular human insulin (RHI)
Time Frame: crossover 5 times over the course of up to 6 weeks
|
Timepoints: 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180 and 240 minutes after administration of TI dosing; 0, 15, 30, 60, 90, 120, 180, 240, 300, 360, 480 and 600 minutes after RHI dosing
|
crossover 5 times over the course of up to 6 weeks
|
Area-under-the-serum glucose infusion rate (GIR AUC0-240min) for TI compared to AUC0-600min for RHI
Time Frame: crossover 5 times over the course of up to 6 weeks
|
Timepoints for TI: 0, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180 and 240 minutes after TI dosing Timepoints: 0, 15, 30, 60, 90, 120, 180, 240, 300, 360, 480 and 600 minutes after RHI dosing
|
crossover 5 times over the course of up to 6 weeks
|
Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations
Time Frame: crossover 5 times for up to 6 weeks
|
crossover 5 times for up to 6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Chief Medical Officer, Mannkind Corporation
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MKC-TI-176
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Regular Human Insulin
-
Eli Lilly and CompanyInsulet CorporationCompletedType 2 Diabetes MellitusUnited States, Puerto Rico
-
PfizerTerminatedDiabetes MellitusUnited States
-
Brown UniversityRecruiting
-
University of Sao PauloCompletedHeart Valve Diseases | Ventricular Dysfunction | Hyperglycaemia During Perioperative PeriodBrazil
-
Mannkind CorporationCompleted
-
Vanderbilt UniversityWithdrawn
-
WockhardtCompletedDiabetes MellitusUnited States
-
Halozyme TherapeuticsCompleted